Literature DB >> 1316796

Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma.

M A Giembycz1, G Dent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1316796     DOI： 10.1111/j.1365-2222.1992.tb03095.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN： 0954-7894            Impact factor:   5.018


× No keyword cloud information.
  20 in total

1.  A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo.

Authors:  N Cooper; M M Teixeira; J Warneck; J M Miotla; R E Wills; D M Macari; R W Gristwood; P G Hellewell
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen.

Authors:  P G Bardin; M A Dorward; F C Lampe; B Franke; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

3.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

Review 4.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

5.  Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.

Authors:  J L Ortiz; J M Vallés; M Martí-Cabrera; J Cortijo; E J Morcillo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

6.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.

Authors:  N Gozzard; A el-Hashim; C M Herd; S M Blake; M Holbrook; B Hughes; G A Higgs; C P Page
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

8.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 9.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

10.  Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation.

Authors:  L Sekut; D Yarnall; S A Stimpson; L S Noel; R Bateman-Fite; R L Clark; M F Brackeen; J A Menius; K M Connolly
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.